ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P ASX 200
7,749.70
0.44%
S&P ASX All Technology
3,127.90
1.92%
Brent Oil
82.07
-0.28%
US Dollar vs AUD
1.50494
0.27%
Bitcoin
67,547.19
-1.03%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Panbela Therapeutics Inc (PBLA)

  7. Panbela Therapeutics Inc (PBLA) News

PBLA

Panbela Therapeutics (PBLA)

Panbela Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PBLA
DateTimeSourceHeadlineSymbolCompany
10/06/202422:00GlobeNewswire Inc.Panbela Announces Oral Presentation at Digestive Disease Week (DDW):NASDAQ:PBLAPanbela Therapeutics Inc
29/05/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
16/05/202406:10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q1 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
06/05/202422:00GlobeNewswire Inc.Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and SulindacNASDAQ:PBLAPanbela Therapeutics Inc
02/05/202406:15GlobeNewswire Inc.Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024NASDAQ:PBLAPanbela Therapeutics Inc
30/04/202422:00GlobeNewswire Inc.Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease WeekNASDAQ:PBLAPanbela Therapeutics Inc
27/04/202406:39Edgar (US Regulatory)Form PRER14A - Preliminary Proxy Soliciting materialsNASDAQ:PBLAPanbela Therapeutics Inc
26/04/202406:36Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:PBLAPanbela Therapeutics Inc
26/04/202406:35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
25/04/202423:09Edgar (US Regulatory)Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securitiesNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202422:02Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
22/04/202422:00GlobeNewswire Inc.Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025NASDAQ:PBLAPanbela Therapeutics Inc
19/04/202406:31Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
18/04/202422:00GlobeNewswire Inc.Panbela Announces Poster Presentation at American Association for Cancer Research:NASDAQ:PBLAPanbela Therapeutics Inc
17/04/202422:36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
17/04/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
17/04/202407:29GlobeNewswire Inc.Panbela Announces Transfer to OTCQB MarketNASDAQ:PBLAPanbela Therapeutics Inc
05/04/202407:17Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
03/04/202415:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PBLAPanbela Therapeutics Inc
30/03/202408:24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:PBLAPanbela Therapeutics Inc
30/03/202408:08Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:PBLAPanbela Therapeutics Inc
27/03/202407:15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:PBLAPanbela Therapeutics Inc
27/03/202407:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
27/03/202407:10GlobeNewswire Inc.Panbela Provides Business Update and Reports Q4 and FY 2024 Financial ResultsNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202422:21IH Market NewsU.S. Index Futures on the Rise, Oil Prices Show StabilityNASDAQ:PBLAPanbela Therapeutics Inc
26/03/202407:15Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:PBLAPanbela Therapeutics Inc
13/03/202407:15GlobeNewswire Inc.Panbela to Host Fourth Quarter and Year End 2023 Earnings Conference Call on March 26, 2024NASDAQ:PBLAPanbela Therapeutics Inc
07/03/202422:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
16/02/202400:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBLAPanbela Therapeutics Inc
16/02/202400:00GlobeNewswire Inc.Panbela Regains Compliance with Nasdaq Listing Standards for Bid Price and Publicly Held Shares RequirementsNASDAQ:PBLAPanbela Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PBLA

Your Recent History

ASX
TLS
Telstra
PM
XAUUSD
Gold vs US Dollar
NYSE
NKE
Nike
ASX
QBE
QBE Insurance
NYSE
DIS
Walt Disney
NASDAQ
MSFT
Microsoft
NYSE
MRK
Merck
FX
AUDJPY
AUD vs Yen
ASX
WES
Wesfarmers
ASX
WBC
Westpac Banking
ASX
FMG
Fortescue
FX
EURAUD
Euro vs AUD
ASX
XMM
S&P ASX 300 Metals and M...
FX
AUDUSD
AUD vs US Dollar
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved